MedTrace Logo

Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma

NCT01272466 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-31

No results posted yet for this study

Summary

Anti-apoptotic proteins from the Bcl-2 family are known to play a key role in oncogenesis and are overexpressed in myeloma cells. Studies have shown that dendritic cells exposed to proteasome inhibition present exogene antigens better than unexposed dendritic cells. Patients with relapse of multiple myeloma will be offered vaccination with peptides derived from antiapoptotic proteins from the Bcl-2 family in combination with an immunostimulatory adjuvant. The vaccination will be given in relation to treatment with the proteasome inhibitor bortezomib.

Conditions

  • Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

peptides derived from antiapoptotic proteins

8 Vaccinations on day 2 and 9 in every bortezomib treatment series

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Lene M Knudsen, M.D · Department of Haematology, Odense University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2015-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272466 on ClinicalTrials.gov